Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies

Immunological Reviews

Volumn 275, Issue 1, 2017, Pages 89-107

  Verkoczy, Laurent ^a   Alt, Frederick W ^b   Tian, Ming ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

B cell lineages; B cell tolerance controls; broadly neutralizing antibodies (bnAbs); CD4 binding site (CD4bs); knockin (KI) mice; sequential immunization

Indexed keywords

ANTIGEN; NEUTRALIZING ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; B LYMPHOCYTE; EXON; GENE EXPRESSION; GENE INSERTION; GENE LOCUS; GENE REARRANGEMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNOGLOBULIN KNOCKIN MOUSE; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS VIRULENCE; ANIMAL; ANIMAL MODEL; GENE TARGETING; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METABOLISM; MOUSE; VIROLOGY;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; B-LYMPHOCYTES; GENE KNOCK-IN TECHNIQUES; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULINS; MICE; MODELS, ANIMAL;

EID: 85010867808     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12505     Document Type: Review

References (147)

1. Excler JL, Ake J, Robb ML, Kim JH, Plotkin SA. Nonneutralizing functional antibodies: a new “old” paradigm for HIV vaccines. Clin Vaccine Immunol. 2014;21:1023–1036.
2. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17:1055–1065.
3. Mascola JR, Haynes BF. HIV-1 neutralizing antibodies: Understanding nature's pathways. Immunol Rev. 2013;254:225–244.
4. Hessell AJ, Poignard P, Hunter M, et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med. 2009;15:951–954.
5. Hessell AJ, Rakasz EG, Poignard P, et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 2009;5:e1000433.
6. Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature. 2012;481:81–84.
7. Haynes BF. New approaches to HIV vaccine development. Curr Opin Immunol. 2015;35:39–47.
8. Hraber P, Seaman MS, Bailer RT, Mascola JR, Montefiori DC, Korber BT. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS (London, England). 2014;28:163–169.
9. Simek MD, Rida W, Priddy FH, et al. Human immunodeficiency virus type 1 elite neutralizers: Individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol. 2009;83:7337–7348.
10. Gray ES, Madiga MC, Hermanus T, et al. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol. 2011;85:4828–4840.
11. Tomaras GD, Binley JM, Gray ES, et al. Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J Virol. 2011;85:11502–11519.
12. Mikell I, Sather DN, Kalams SA, Altfeld M, Alter G, Stamatatos L. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog. 2011;7:e1001251.
13. Burton DR, Hangartner L. Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design. Annu Rev Immunol. 2016;34:635–659.
14. Burton DR, Mascola JR. Antibody responses to envelope glycoproteins in HIV-1 infection. Nat Immunol. 2015;16:571–576.
15. Pejchal R, Walker LM, Stanfield RL, et al. Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc Natl Acad Sci USA. 2010;107:11483–11488.
16. Alam SM, Morelli M, Dennison SM, et al. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc Natl Acad Sci USA. 2009;106:20234–20239.
17. Mouquet H, Scheid JF, Zoller MJ, et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature. 2010;467:591–595.
18. Klein F, Diskin R, Scheid JF, et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell. 2013;153:126–138.
19. Kwong PD, Mascola JR. Human antibodies that neutralize HIV-1: Identification, structures, and B cell ontogenies. Immunity. 2012;37:412–425.
20. West AP Jr, Scharf L, Scheid JF, Klein F, Bjorkman PJ, Nussenzweig MC. Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell. 2014;156:633–648.
21. Haynes BF, Moody MA, Alam M, et al. Progress in HIV-1 vaccine development. J Allergy Clin Immunol. 2014;134:3–10.
22. Verkoczy L, Kelsoe G, Moody MA, Haynes BF. Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. Curr Opin Immunol. 2011;23:383–390.
23. Verkoczy L, Diaz M. Autoreactivity in HIV-1 broadly neutralizing antibodies: Implications for their function and induction by vaccination. Curr Opin HIV AIDS. 2014;9:224–234.
24. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science (New York, NY). 2003;301:1374–1377.
25. Meffre E, Milili M, Blanco-Betancourt C, Antunes H, Nussenzweig MC, Schiff C. Immunoglobulin heavy chain expression shapes the B cell receptor repertoire in human B cell development. J Clin Invest. 2001;108:879–886.
26. Ivanov II, Schelonka RL, Zhuang Y, Gartland GL, Zemlin M, Schroeder HW Jr. Development of the expressed Ig CDR-H3 repertoire is marked by focusing of constraints in length, amino acid use, and charge that are first established in early B cell progenitors. J Immunol. 2005;174:7773–7780.
27. Shiokawa S, Mortari F, Lima JO, et al. IgM heavy chain complementarity-determining region 3 diversity is constrained by genetic and somatic mechanisms until two months after birth. J Immunol. 1999;162:6060–6070.
28. Kepler TB, Perelson AS. Somatic hypermutation in B cells: An optimal control treatment. J Theor Biol. 1993;164:37–64.
29. Batista FD, Neuberger MS. Affinity dependence of the B cell response to antigen: A threshold, a ceiling, and the importance of off-rate. Immunity. 1998;8:751–759.
30. Sabouri Z, Schofield P, Horikawa K, et al. Redemption of autoantibodies on anergic B cells by variable-region glycosylation and mutation away from self-reactivity. 2014;111:E2567–E2575.
31. Haynes BF, Verkoczy L, Kelsoe G. Redemption of autoreactive B cells. Proc Natl Acad Sci USA. 2014;111:9022–9023.
32. Verkoczy L, Kelsoe G, Haynes BF. HIV-1 envelope gp41 broadly neutralizing antibodies: Hurdles for vaccine development. PLoS Pathog. 2014;10:e1004073.
33. Sok D, Laserson U, Laserson J, et al. The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies. PLoS Pathog. 2013;9:e1003754.
34. Bonsignori M, Alam SM, Liao HX, et al. HIV-1 antibodies from infection and vaccination: Insights for guiding vaccine design. Trends Microbiol. 2012;20:532–539.
35. Liao HX, Lynch R, Zhou T, et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature. 2013;496:469–476.
36. Doria-Rose NA, Schramm CA, Gorman J, et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature. 2014;509:55–62.
37. Verkoczy L, Chen Y, Zhang J, et al. Induction of HIV-1 broad neutralizing antibodies in 2F5 knock-in mice: Selection against membrane proximal external region-associated autoreactivity limits T-dependent responses. J Immunol. 2013;191:2538–2550.
38. Moir S, Fauci AS. Insights into B cells and HIV-specific B-cell responses in HIV-infected individuals. Immunol Rev. 2013;254:207–224.
39. Levesque MC, Moody MA, Hwang KK, et al. Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med. 2009;6:e1000107.
40. Georgiev IS, Rudicell RS, Saunders KO, et al. Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline. J Immunol. 2014;192:1100–1106.
41. Seo SJ, Fields ML, Buckler JL, et al. The impact of T helper and T regulatory cells on the regulation of anti-double-stranded DNA B cells. Immunity. 2002;16:535–546.
42. Cooke MP, Heath AW, Shokat KM, et al. Immunoglobulin signal transduction guides the specificity of B cell-T cell interactions and is blocked in tolerant self-reactive B cells. J Exp Med. 1994;179:425–438.
43. Sekiguchi DR, Jainandunsing SM, Fields ML, et al. Chronic graft-versus-host in Ig knockin transgenic mice abrogates B cell tolerance in anti-double-stranded DNA B cells. J Immunol. 2002;168:4142–4153.
44. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature. 2002;416:603–607.
45. Lau CM, Broughton C, Tabor AS, et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med. 2005;202:1171–1177.
46. Doria-Rose NA, Louder MK, Yang Z, et al. HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes. J Virol. 2012;86:3393–3397.
47. Bonsignori M, Montefiori DC, Wu X, et al. Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: Implications for vaccine design. J Virol. 2012;86:4688–4692.
48. de Taeye SW, Moore JP, Sanders RW. HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies. Trends Immunol. 2016;37:221–232.
49. Sliepen K, Sanders RW. HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies. Expert review of vaccines. 2016;15:349–365.
50. Goepfert PA, Elizaga ML, Sato A, et al. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis. 2011;203:610–619.
51. Tong T, Crooks ET, Osawa K, Binley JM. HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes. J Virol. 2012;86:3574–3587.
52. Lifson JD, Piatak M Jr, Rossio JL, et al. Whole inactivated SIV virion vaccines with functional envelope glycoproteins: Safety, immunogenicity, and activity against intrarectal challenge. J Med Primatol. 2002;31:205–216.
53. Sanders RW, van Gils MJ, Derking R, et al. HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science (New York, NY). 2015;349:aac4223.
54. Hoot S, McGuire AT, Cohen KW, et al. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog. 2013;9:e1003106.
55. McGuire AT, Hoot S, Dreyer AM, et al. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J Exp Med. 2013;210:655–663.
56. Jardine J, Julien JP, Menis S, et al. Rational HIV immunogen design to target specific germline B cell receptors. Science (New York, NY). 2013;340:711–716.
57. Alam SM, Liao HX, Dennison SM, et al. Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation. J Virol. 2011;85:11725–11731.
58. Alam SM, Dennison SM, Aussedat B, et al. Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors. Proc Natl Acad Sci USA. 2013;110:18214–18219.
59. McElrath MJ, Haynes BF. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity. 2010;33:542–554.
60. Huang Y, DiazGranados C, Janes H, et al. Selection of HIV vaccine candidates for concurrent testing in an efficacy trial. Curr Opin Virol. 2016;17:57–65.
61. Haynes BF, Kelsoe G, Harrison SC, Kepler TB. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol. 2012;30:423–433.
62. Wang S, Mata-Fink J, Kriegsman B, et al. Manipulating the selection forces during affinity maturation to generate cross-reactive HIV antibodies. Cell. 2015;160:785–797.
63. Hartley SB, Crosbie J, Brink R, Kantor AB, Basten A, Goodnow CC. Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens. Nature. 1991;353:765–769.
64. Chen C, Nagy Z, Radic MZ, et al. The site and stage of anti-DNA B-cell deletion. Nature. 1995;373:252–255.
65. Li H, Jiang Y, Prak EL, Radic M, Weigert M. Editors and editing of anti-DNA receptors. Immunity. 2001;15:947–957.
66. Russell DM, Dembic Z, Morahan G, Miller JF, Burki K, Nemazee D. Peripheral deletion of self-reactive B cells. Nature. 1991;354:308–311.
67. Murakami M, Tsubata T, Okamoto M, et al. Antigen-induced apoptotic death of Ly-1 B cells responsible for autoimmune disease in transgenic mice. Nature. 1992;357:77–80.
68. Shlomchik MJ. Sites and stages of autoreactive B cell activation and regulation. Immunity. 2008;28:18–28.
69. Goodnow CC. Transgenic mice and analysis of B-cell tolerance. Annu Rev Immunol. 1992;10:489–518.
70. Nemazee DA, Burki K. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature. 1989;337:562–566.
71. Erikson J, Radic MZ, Camper SA, Hardy RR, Carmack C, Weigert M. Expression of anti-DNA immunoglobulin transgenes in non-autoimmune mice. Nature. 1991;349:331–334.
72. Okamoto M, Murakami M, Shimizu A, et al. A transgenic model of autoimmune hemolytic anemia. J Exp Med. 1992;175:71–79.
73. Tiegs SL, Russell DM, Nemazee D. Receptor editing in self-reactive bone marrow B cells. J Exp Med. 1993;177:1009–1020.
74. Gay D, Saunders T, Camper S, Weigert M. Receptor editing: An approach by autoreactive B cells to escape tolerance. J Exp Med. 1993;177:999–1008.
75. Chen C, Nagy Z, Prak EL, Weigert M. Immunoglobulin heavy chain gene replacement: A mechanism of receptor editing. Immunity. 1995;3:747–755.
76. Goodnow CC, Crosbie J, Adelstein S, et al. Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. Nature. 1988;334:676–682.
77. Goodnow CC, Crosbie J, Jorgensen H, Brink RA, Basten A. Induction of self-tolerance in mature peripheral B lymphocytes. Nature. 1989;342:385–391.
78. Cyster JG, Hartley SB, Goodnow CC. Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire. Nature. 1994;371:389–395.
79. Li Y, Li H, Weigert M. Autoreactive B cells in the marginal zone that express dual receptors. J Exp Med. 2002;195:181–188.
80. Haynes BF, Fleming J, St Clair EW, et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science (New York, NY). 2005;308:1906–1908.
81. Haynes BF, Moody MA, Verkoczy L, Kelsoe G, Alam SM. Antibody polyspecificity and neutralization of HIV-1: A hypothesis. Hum Antibodies. 2005;14:59–67.
82. Braun U, Rajewsky K, Pelanda R. Different sensitivity to receptor editing of B cells from mice hemizygous or homozygous for targeted Ig transgenes. Proc Natl Acad Sci USA. 2000;97:7429–7434.
83. Verkoczy L, Diaz M, Holl TM, et al. Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. Proc Natl Acad Sci USA. 2010;107:181–186.
84. Verkoczy L, Chen Y, Bouton-Verville H, et al. Rescue of HIV-1 broad neutralizing antibody-expressing B cells in 2F5 VH x VL knockin mice reveals multiple tolerance controls. J Immunol. 2011;187:3785–3797.
85. Chen Y, Zhang J, Hwang KK, et al. Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10. J Immunol. 2013;191:1260–1275.
86. Doyle-Cooper C, Hudson KE, Cooper AB, et al. Immune tolerance negatively regulates B cells in knock-in mice expressing broadly neutralizing HIV antibody 4E10. J Immunol. 2013;191:3186–3191.
87. Finton KA, Larimore K, Larman HB, et al. Autoreactivity and exceptional CDR plasticity (but not unusual polyspecificity) hinder elicitation of the anti-HIV antibody 4E10. PLoS Pathog. 2013;9:e1003639.
88. Ota T, Doyle-Cooper C, Cooper AB, et al. B cells from knock-in mice expressing broadly neutralizing HIV antibody b12 carry an innocuous B cell receptor responsive to HIV vaccine candidates. J Immunol. 2013;191:3179–3185.
89. Cambier JC, Gauld SB, Merrell KT, Vilen BJ. B-cell anergy: From transgenic models to naturally occurring anergic B cells? Nat Rev Immunol. 2007;7:633–643.
90. Zhang R, Verkoczy L, Wiehe K, et al. Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages. Sci Transl Med. 2016;8:336ra362.
91. Kelsoe G, Verkoczy L, Haynes BF. Immune System Regulation in the Induction of Broadly Neutralizing HIV-1 Antibodies. Vaccines (Basel). 2014;2:1–14.
92. Lang J, Jackson M, Teyton L, Brunmark A, Kane K, Nemazee D. B cells are exquisitely sensitive to central tolerance and receptor editing induced by ultralow affinity, membrane-bound antigen. J Exp Med. 1996;184:1685–1697.
93. McGuire AT, Gray MD, Dosenovic P, et al. Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice. Nat Commun. 2016;7:10618.
94. Liu M, Yang G, Wiehe K, et al. Polyreactivity and autoreactivity among HIV-1 antibodies. J Virol. 2015;89:784–798.
95. Huang J, Ofek G, Laub L, et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature. 2012;491:406–412.
96. Wu X, Yang ZY, Li Y, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science (New York, NY). 2010;329:856–861.
97. Zhou T, Georgiev I, Wu X, et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science (New York, NY). 2010;329:811–817.
98. Kaye BR. Rheumatologic manifestations of infection with human immunodeficiency virus (HIV). Ann Intern Med. 1989;111:158–167.
99. Barthel HR, Wallace DJ. False-positive human immunodeficiency virus testing in patients with lupus erythematosus. Semin Arthritis Rheum. 1993;23:1–7.
100. Mylonakis E, Paliou M, Greenbough TC, Flaningan TP, Letvin NL, Rich JD. Report of a false-positive HIV test result and the potential use of additional tests in establishing HIV serostatus. Arch Intern Med. 2000;160:2386–2388.
101. Palacios R, Santos J, Valdivielso P, Marquez M. Human immunodeficiency virus infection and systemic lupus erythematosus. An unusual case and a review of the literature. Lupus. 2002;11:60–63.
102. Calza L, Manfredi R, Colangeli V, D'Antuono A, Passarini B, Chiodo F. Systemic and discoid lupus erythematosus in HIV-infected patients treated with highly active antiretroviral therapy. Int J STD AIDS. 2003;14:356–359.
103. Moody MA, Isabela Pedroza-Pacheco, Nathan A, et al. Immune perturbations in HIV-1–infected individuals who make broadly neutralizing antibodies. Science Immunology. 2016;1:aag0851.
104. Goodnow CC, Brink R, Adams E. Breakdown of self-tolerance in anergic B lymphocytes. Nature. 1991;352:532–536.
105. Dosenovic P, Soldemo M, Scholz JL, et al. BLyS-mediated modulation of naive B cell subsets impacts HIV Env-induced antibody responses. J Immunol. 2012;188:6018–6026.
106. Gupta S, Clark ES, Termini JM, et al. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers. J Virol. 2015;89:4158–4169.
107. Chen Y, Zhang J, Bouton-Verville H, et al. Lipid components in MPER-based immunization regimens are critical for inducing broadly neutralizing antibody responses in 2F5 and 4E10 knock-in Mice. AIDS Res Hum Retroviruses. 2013;29:20–21.
108. Yang G, Holl TM, Liu Y, et al. Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. J Exp Med. 2013;210:241–256.
109. Li Y, O'Dell S, Walker LM, et al. Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J Virol. 2011;85:8954–8967.
110. Vcelar B, Stiegler G, Wolf HM, et al. Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data. AIDS (London, England). 2007;21:2161–2170.
111. Scheid JF, Mouquet H, Ueberheide B, et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science (New York, NY). 2011;333:1633–1637.
112. Zhou T, Zhu J, Wu X, et al. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity. 2013;39:245–258.
113. Zhou T, Lynch RM, Chen L, et al. Structural repertoire of HIV-1-neutralizing antibodies targeting the CD4 supersite in 14 donors. Cell. 2015;161:1280–1292.
114. Jardine JG, Sok D, Julien JP, et al. Minimally mutated HIV-1 broadly neutralizing antibodies to guide reductionist vaccine design. PLoS Pathog. 2016;12:e1005815.
115. Dimitrov DS. Therapeutic antibodies, vaccines and antibodyomes. mAbs. 2010;2:347–356.
116. Xiao X, Chen W, Feng Y, et al. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: Implications for evasion of immune responses and design of vaccine immunogens. Biochem Biophys Res Commun. 2009;390:404–409.
117. Jardine JG, Kulp DW, Havenar-Daughton C, et al. HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. Science (New York, NY). 2016;351:1458–1463.
118. Jardine JG, Ota T, Sok D, et al. HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science (New York, NY). 2015;349:156–161.
119. Briney B, Sok D, Jardine JG, et al. Tailored Immunogens direct affinity maruration toward HIV neutralizing antibodies. Cell. 2016;166:1459–1470.
120. Dosenovic P, von Boehmer L, Escolano A, et al. Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice. Cell. 2015;161:1505–1515.
121. Alt FW, Zhang Y, Meng FL, Guo C, Schwer B. Mechanisms of programmed DNA lesions and genomic instability in the immune system. Cell. 2013;152:417–429.
122. Tian M, Cheng C, Chen X, et al. Induction of HIV neutralizing antibody lineages in mice with diverse precursor repertoires. Cell. 2016;166:1471–1484.
123. Sok D, Briney B, Jardine JG, et al. Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice. Science (New York, NY). 2016;356:1557–1560.
124. Arnaout R, Lee W, Cahill P, et al. High-resolution description of antibody heavy-chain repertoires in humans. PLoS ONE. 2011;6:e22365.
125. DeKosky BJ, Kojima T, Rodin A. In-depth determination and analysis of the human paired heavy- and light-chain antibody repertoire. Nat Med. 2015;21:86–91.
126. Lee EC, Liang Q, Ali H, et al. Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery. Nat Biotechnol. 2014;32:356–363.
127. Walker LM, Huber M, Doores KJ, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 2011;477:466–470.
128. Mouquet H, Scharf L, Euler Z, et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci USA. 2012;109:E3268–E3277.
129. Garces F, Sok D, Kong L, et al. Structural evolution of glycan recognition by a family of potent HIV antibodies. Cell. 2014;159:69–79.
130. Garces F, Lee JH, de Val N, et al. Affinity maturation of a potent family of HIV antibodies is primarily focused on accommodating or avoiding glycans. Immunity. 2015;43:1053–1063.
131. Steichen JM, Kulp DW, Tokatlian T, et al. HIV vaccine design to target germline precursors of glycan-dependent broadly neutralizing antibodies. Immunity. 2016;166:1445–1458.
132. Escolano A, Steichen JM, Dosenovic P, et al. Sequential immunization elicits broadly neutralizing anti-HIV antibodies in Ig knock-in mice. Cell. 2016;166:1445–1458.
133. Pancera M, Shahzad-Ul-Hussan S, Doria-Rose NA, et al. Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat Struct Mol Biol. 2013;20:804–813.
134. Julien JP, Lee JH, Cupo A, et al. Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc Natl Acad Sci USA. 2013;110:4351–4356.
135. Murphy AJ, Macdonald LE, Stevens S, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci USA. 2014;111:5153–5158.
136. Macdonald LE, Karow M, Stevens S, et al. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc Natl Acad Sci USA. 2014;111:5147–5152.
137. Li H, Wang S, Kong R, et al. Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. Proc Natl Acad Sci USA. 2016;113:E3413–E3422.
138. Kepler TB. Reconstructing a B-cell clonal lineage. I. Statistical inference of unobserved ancestors. F1000 Res. 2013;2:103.
139. Briney BS, Willis JR, Crowe JE Jr. Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes. PLoS ONE. 2012;7:e36750.
140. Chen J, Lansford R, Stewart V, Young F, Alt FW. RAG-2-deficient blastocyst complementation: An assay of gene function in lymphocyte development. Proc Natl Acad Sci USA. 1993;90:4528–4532.
141. Mietzner B, Tsuiji M, Scheid J, et al. Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors. Proc Natl Acad Sci USA. 2008;105:9727–9732.
142. Shlomchik M, Mascelli M, Shan H, et al. Anti-DNA antibodies from autoimmune mice arise by clonal expansion and somatic mutation. J Exp Med. 1990;171:265–292.
143. + memory B cells. Immunity. 2007;26:205–213.
144. Kraus M, Alimzhanov MB, Rajewsky N, Rajewsky K. Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell. 2004;117:787–800.
145. Kepler TB, Liao HX, Alam SM, et al. Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies. Cell Host Microbe. 2014;16:304–313.
146. Yeap LS, Hwang JK, Du Z, et al. Sequence-intrinsic mechanisms that target AID mutational outcomes on antibody genes. Cell. 2015;163:1124–1137.
147. Daly J, Bebenek K, Watt DL, et al. Altered Ig hypermutation pattern and frequency in complementary mouse models of DNA polymerase zeta activity. J Immunol. 2012;188:5528–5537.